IPA Aug 2024 2.500 put
| Previous close | 1.3000 |
| Open | 1.3000 |
| Bid | 1.2000 |
| Ask | 1.5000 |
| Strike | 2.50 |
| Expiry date | 2024-08-16 |
| Day's range | 1.3000 - 1.3000 |
| Contract range | N/A |
| Volume | |
| Open interest | 118 |
Business WireInterSystems and IPA’s Subsidiary BioStrand Collaborate to Unveil the Innovative Integration of Vector Search with LENSai for AI-Driven Healthcare Applications
VICTORIA, British Columbia, March 28, 2024--IPA (IMMUNOPRECISE ANTIBODIES LTD.) (the "Company" or "IPA") (NASDAQ: IPA), InterSystems, a creative data technology provider dedicated to helping customers solve their most critical scalability, interoperability, and speed challenges, together with ImmunoPrecise Antibodies Ltd. (IPA) (NASDAQ: IPA), an artificial intelligence-driven biotherapeutic research and technology company, are thrilled to announce a landmark collaboration. This collaboration int
Business WireIPA Acquires the Carterra LSA® Instrument to Enhance Antibody Discovery and Bolster Its AI Developments
VICTORIA, British Columbia, March 20, 2024--IPA (IMMUNOPRECISE ANTIBODIES LTD.) (the "Company" or "IPA") (NASDAQ: IPA), an artificial intelligence-driven biotherapeutic research and technology company, today announced that it has acquired the LSA® instrument platform from Carterra®, a leading provider of high-throughput large and small molecule screening and characterization solutions. This instrument allows for high throughput surface plasmon resonance-based antibody characterizations thereby s
Business WireIPA Reports Financial Results and Recent Business Highlights for Third Quarter Fiscal Year 2024*
VICTORIA, British Columbia, March 14, 2024--IPA (IMMUNOPRECISE ANTIBODIES LTD.) (the "Company" or "IPA") (NASDAQ: IPA), an artificial intelligence-driven biotherapeutic research and technology company, today reported financial results for its third quarter of the 2024 fiscal year ("FY24"), which ended January 31, 2024.
